Felzartamab

4 trials 2 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

2 Completed trials

2 Sponsors

12 Countries

Phase III

Phase II

Phase III: 2 Phase II: 2

Indications tested

IgA nephropathy 1 Kidney transplant rejection 1

Sponsors using this IMP

Biogen Idec Research Limited 3 Istituto Di Ricerche Farmacologiche Mario Negri 1

All trials

4 total

A Trial of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI) - (TRANSPIRE) Recruiting

2025-521742-15-00 Phase II 5 countries Biogen Idec Research Limited
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting

2024-519345-30-00 Phase III 11 countries Biogen Idec Research Limited
A Trial of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) Ended

2024-519095-66-00 Phase III 5 countries Biogen Idec Research Limited
Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Th… Ended

2024-513744-28-00 Phase II 1 country Istituto Di Ricerche Farmacologiche Mario Negri

Showing 1–4 of 4 trials

← All drugs A–Z